Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PPARA | Q07869 | 14/20 | 0.68 |
| ▸ | PPARG | P37231 | 13/20 | 0.68 |
| ▸ | PPARD | Q03181 | 8/20 | 0.68 |
| ▸ | EPHX2 | P34913 | 3/20 | 0.42 |
| ▸ | NR1H4 | Q96RI1 | 3/20 | 0.42 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.40 |
| ▸ | MEN1 | O00255 | 1/20 | 0.39 |
| ▸ | NPC1 | O15118 | 1/20 | 0.39 |
| ▸ | RAB9A | P51151 | 1/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4688939 | 0.90 | PPARA (0.79) | PPARAPPARGPPARD | |
| SCHEMBL4695991 | 0.90 | PPARG (0.84) | PPARAPPARGPPARD | |
| SCHEMBL4787025 | 0.87 | PPARA (0.80) | PPARAPPARGPPARDEPHX2NR1H4 | |
| SCHEMBL4694880 | 0.85 | PPARG (0.67) | PPARAPPARGPPARDEPHX2NR1H4 | |
| SCHEMBL2812116 | 0.81 | PPARG (1.00) | PPARAPPARGPPARD | |
| SCHEMBL4692439 | 0.80 | PPARG (0.84) | PPARAPPARGPPARD | |
| SCHEMBL4688206 | 0.80 | PPARG (0.72) | PPARAPPARGPPARDMEN1KMT2A | |
| SCHEMBL4688952 | 0.78 | PPARG (0.65) | PPARAPPARGPPARDRAB9A | |
| SCHEMBL4689778 | 0.78 | PPARG (0.84) | PPARAPPARGPPARD | |
| SCHEMBL4693223 | 0.78 | PPARG (0.55) | PPARAPPARGPPARDL3MBTL1MEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1685113-B1 | SUBSTITUTED PYRAZOLES AS PPAR AGONISTS | SMITHKLINE BEECHAM CORP (US) | 2008-07-30 | — | — | EP | disclosed |
| EP-1685113-B1 | SUBSTITUTED PYRAZOLES AS PPAR AGONISTS | SMITHKLINE BEECHAM CORP (US) | 2008-07-30 | — | — | EP | disclosed |
| US-20080021030-A1 | Substituted Pyrazoles As Ppar Agonists | SMITHKLINE BEECHAM CORPORATION | 2008-01-24 | — | — | US | disclosed |
| US-20080021030-A1 | Substituted Pyrazoles As Ppar Agonists | SMITHKLINE BEECHAM CORPORATION | 2008-01-24 | — | — | US | disclosed |
| US-20080021030-A1 | Substituted Pyrazoles As Ppar Agonists | SMITHKLINE BEECHAM CORPORATION | 2008-01-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080021030-A1 | Substituted Pyrazoles As Ppar Agonists | PPARD, PPARA, PPARG | PPARA 2/4885PPARG 3/4885PPARD 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.